Gleevec For What? Imatinib NDA For PAH Will Face Safety Questions At Advisory Panel
Novartis said there was a higher rate of unspecified serious adverse events in the active arm of the pivotal trial for pulmonary arterial hypertension.
Original Article: Gleevec For What? Imatinib NDA For PAH Will Face Safety Questions At Advisory Panel
NEXT ARTICLE